Hematological malignancy and pregnancy: a single-institution experience of 21 cases.

Abstract

The incidence of hematological malignancies during pregnancy is low, and treatment in this setting is problematic. This study observed 21 pregnancies in 18 patients with hematological malignancies. Patients' ages were between 19 and 43 (median 25) years. Two pregnancies ended with spontaneous abortion, one pregnancy ended with in utero death, three therapeutic abortions were carried out, and 15 infants were born alive but three of them died later. The median birth weight was 2.47 kg. Twelve babies survived to a median age of 36 (range 4-117) months. Eight babies were exposed to chemotherapy during the in utero period. One baby was exposed to chemotherapy during all the trimesters and was born prematurely and later died because of intracranial bleeding. Four babies were exposed to chemotherapy during the first trimester, one of them had low birth weight and floating thumb malformation, two of them had only low birth weight, and one was born healthy, but died at 3 months of age as a result of severe gastroenteritis. Two babies were exposed to chemotherapy during the second and third trimesters; one of them had low birth weight, and the other pregnancy ended in in utero death. One infant was exposed to chemotherapy during the third trimester and was born at term, but died because of pulmonary hemorrhage. We concluded that chemotherapy during all trimesters of pregnancy carries a significant risk for an unfavorable outcome.

• Authors: I Dilek, N Topcu, C Demir, A Bay, K Uzun, A Gul, A Faik Oner, S Ugras
• Journal: Clinical and laboratory haematology (Clin Lab Haematol) Vol. 28 Issue 3 Pg. 170-6 (Jun 2006) ISSN: 0141-9854 [Print] England
• PMID: 16706933 (Publication Type: Case Reports, Journal Article)

Topics

• Abortion, Spontaneous (chemically induced)
• Abortion, Therapeutic
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Fatal Outcome
• Female
• Fetus (abnormalities, drug effects)
• Hodgkin Disease (drug therapy)
• Humans
• Infant, Newborn
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Leukemia, Myeloid, Acute (drug therapy)
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Pregnancy
• Pregnancy Complications, Hematologic (drug therapy)
• Pregnancy Complications, Neoplastic (drug therapy)